Hematology and Oncology Book




Aka: Andexxa, Inactivated Recombinant Factor Xa, Andexanet alfa
  1. See Also
    1. Emergent Reversal of Anticoagulation
    2. Factor Xa Inhibitor
    3. Eliquis (Apixaban)
    4. Xarelto (Rivaroxaban)
  2. Background
    1. Planned release 2018 in U.S.
  3. Mechanism
    1. Antidote for Eliquis (Apixaban) or Xarelto (Rivaroxaban), but not other Factor Xa Inhibitors
    2. Andexxa is a Inactivated Recombinant Factor Xa decoy protein that binds Factor Xa Inhibitors
  4. Efficacy
    1. Limits progression of bleeding within 12 hours of dose (onset as early as 1 hour)
    2. Ineffective in the 25% of patients who have low anti-Factor Xa Inhibitor
  5. Adverse Effects
    1. Expensive: $25,000 to 50,000 per patient
    2. Risk of Hypercoagulability complications (CVA, VTE)
  6. References
    1. (2018) Presc Lett 25(7): 37-8
    2. Connolly (2019) N Engl J Med 380(14):1326-35 +PMID:30730782 [PubMed]

You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree